Perrigo Reports Q1 Sales Decline Amid Strategic Changes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PRGO?
Source: Newsfilter
- Sales Decline: Perrigo reported net sales of $969 million for Q1, a 7.2% year-over-year decline primarily due to reduced consumption in the U.S. and Europe, particularly from lower seasonal incidence of cough and cold, impacting overall performance.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, primarily due to decreased sales volumes in the Self Care segment and prior-year manufacturing volume headwinds, indicating challenges in cost management.
- Increased Operating Loss: The company reported an operating loss of $372.3 million for the first quarter, largely driven by a $330.8 million goodwill impairment charge, reflecting significant financial pressure during the transformation process.
- Strategic Adjustments and Outlook: Despite challenges, Perrigo maintains its full-year 2026 outlook, expecting benefits in the second half from previously stated growth initiatives and the Operational Enhancement Program, demonstrating confidence in future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.720
Low
18.00
Averages
20.33
High
23.00
Current: 11.720
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
Perrigo Reports Q1 Sales Decline Amid Strategic Changes
- Sales Decline: Perrigo reported net sales of $969 million for Q1, a 7.2% year-over-year decline primarily due to reduced consumption in the U.S. and Europe, particularly from lower seasonal incidence of cough and cold, impacting overall performance.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, primarily due to decreased sales volumes in the Self Care segment and prior-year manufacturing volume headwinds, indicating challenges in cost management.
- Increased Operating Loss: The company reported an operating loss of $372.3 million for the first quarter, largely driven by a $330.8 million goodwill impairment charge, reflecting significant financial pressure during the transformation process.
- Strategic Adjustments and Outlook: Despite challenges, Perrigo maintains its full-year 2026 outlook, expecting benefits in the second half from previously stated growth initiatives and the Operational Enhancement Program, demonstrating confidence in future performance.
See More
Perrigo Set to Announce Q1 Earnings Results
- Earnings Announcement: Perrigo (PRGO) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.31, reflecting a 48.3% year-over-year decline, while revenue is expected to remain flat at $1.04 billion, indicating challenges in profitability.
- Performance Expectations: Over the past two years, Perrigo has beaten EPS estimates 63% of the time, but only 38% for revenue, suggesting instability in revenue growth that could impact investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward, reflecting a cautious market outlook on Perrigo's future performance, potentially leading to stock price volatility.
- Market Dynamics: Perrigo has gained attention amid takeover speculation, and although the FDA has confirmed the safety of U.S. baby formula supplies, such speculation may influence investor perceptions of the company's future growth prospects.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
Perrigo Sells Dermacosmetics Business for €332.6 Million, Reducing Debt by €306 Million
- Transaction Overview: Perrigo has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash and €27 million contingent on sales milestones, marking a significant step in the company's strategic transformation.
- Enhanced Financial Flexibility: The transaction is expected to yield approximately €306 million in net proceeds, primarily aimed at debt reduction, thereby enhancing the company's financial flexibility and strengthening its balance sheet to support sustainable future growth.
- Market Performance: In 2025, Perrigo's Dermacosmetics business generated around €120 million in net sales, representing about 5% of the company's adjusted operating income, allowing Perrigo to focus more on its core business areas following the sale.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction is a crucial milestone in executing the Three-S plan (Stabilize, Streamline, Strengthen), aimed at enhancing competitive advantages and shareholder value through portfolio streamlining.
See More
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
Perrigo Reports Q1 Sales Decline Amid Strategic Changes
- Sales Decline: Perrigo reported net sales of $969 million for Q1, a 7.2% year-over-year decline primarily due to reduced consumption in the U.S. and Europe, particularly from lower seasonal incidence of cough and cold, impacting overall performance.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, primarily due to decreased sales volumes in the Self Care segment and prior-year manufacturing volume headwinds, indicating challenges in cost management.
- Increased Operating Loss: The company reported an operating loss of $372.3 million for the first quarter, largely driven by a $330.8 million goodwill impairment charge, reflecting significant financial pressure during the transformation process.
- Strategic Adjustments and Outlook: Despite challenges, Perrigo maintains its full-year 2026 outlook, expecting benefits in the second half from previously stated growth initiatives and the Operational Enhancement Program, demonstrating confidence in future performance.
See More
Perrigo Set to Announce Q1 Earnings Results
- Earnings Announcement: Perrigo (PRGO) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.31, reflecting a 48.3% year-over-year decline, while revenue is expected to remain flat at $1.04 billion, indicating challenges in profitability.
- Performance Expectations: Over the past two years, Perrigo has beaten EPS estimates 63% of the time, but only 38% for revenue, suggesting instability in revenue growth that could impact investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward, reflecting a cautious market outlook on Perrigo's future performance, potentially leading to stock price volatility.
- Market Dynamics: Perrigo has gained attention amid takeover speculation, and although the FDA has confirmed the safety of U.S. baby formula supplies, such speculation may influence investor perceptions of the company's future growth prospects.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
Perrigo Sells Dermacosmetics Business for €332.6 Million, Reducing Debt by €306 Million
- Transaction Overview: Perrigo has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash and €27 million contingent on sales milestones, marking a significant step in the company's strategic transformation.
- Enhanced Financial Flexibility: The transaction is expected to yield approximately €306 million in net proceeds, primarily aimed at debt reduction, thereby enhancing the company's financial flexibility and strengthening its balance sheet to support sustainable future growth.
- Market Performance: In 2025, Perrigo's Dermacosmetics business generated around €120 million in net sales, representing about 5% of the company's adjusted operating income, allowing Perrigo to focus more on its core business areas following the sale.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction is a crucial milestone in executing the Three-S plan (Stabilize, Streamline, Strengthen), aimed at enhancing competitive advantages and shareholder value through portfolio streamlining.
See More
